Cargando…
IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?
Autores principales: | Kow, Chia Siang, Zaihan, Abdullah Faiz, Ramachandram, Dinesh Sangarran, Hasan, Syed Shahzad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491934/ https://www.ncbi.nlm.nih.gov/pubmed/34628129 http://dx.doi.org/10.1016/j.cyto.2021.155730 |
Ejemplares similares
-
The use of corticosteroids in patients with COVID-19 vaccine–related cerebral venous thrombosis
por: Kow, Chia Siang, et al.
Publicado: (2022) -
Use of aspirin for primary prevention in patients with diabetes during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2021) -
Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis
por: Kow, Chia Siang, et al.
Publicado: (2021) -
Colchicine for COVID-19: Hype or hope?
por: Kow, Chia Siang, et al.
Publicado: (2022) -
Insulin therapy in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)